Beacon Biosignals

Beacon Biosignals specializes in an EEG neurobiomarker platform designed to accelerate clinical trials and facilitate new treatments for patients with neurological and psychiatric diseases. The company offers quantitative assessments of treatment impacts on EEG and sleep data to ensure clinical endpoints are met. By understanding pharmacokinetic and pharmacodynamic relationships with brain activity, Beacon Biosignals identifies doses with optimal efficacy and safety profiles and selects optimal patient populations for clinical trials. The platform is powered by an end-to-end augmented EEG system, including products like the Dreem Headband, which is FDA 510(k) cleared for scalable sleep monitoring in clinical trials.

Utilizing state-of-the-art machine learning and a world-class Clinico-EEG database, Beacon Biosignals analyzes existing EEG data to gain insights into mechanisms, PK/PD relationships, and patient stratification. This analysis guides further development efforts, demonstrates target engagement, and informs dose selection, thereby improving the probability of trial and regulatory success. The company also enhances understanding of treatment efficacy and guides label expansion for new therapeutic applications.

Operating in the fields of neurology, psychiatry, sleep, and immunology, Beacon Biosignals partners with biopharma companies, academic medical centers, and neurotechnology developers to improve the diagnosis and treatment of neurological and psychiatric diseases. The company provides advanced EEG analytics and at-home brain monitoring for any stage of clinical studies, empowering academic partners with cutting-edge machine learning algorithms and scalable solutions for data acquisition.

Beacon Biosignals offers a scalable EEG analytics platform aimed at accelerating the development of therapies in neurology, psychiatry, and sleep medicine. The platform captures quantitative EEG endpoints to increase the probability of success at each stage of drug development. The company develops and validates neurobiomarkers to improve cohort selection, de-confound standard clinical assessments, and identify novel endpoints. Their machine learning algorithms are specifically built for brain data and can predict expert consensus on EEG events more accurately and reliably than individual experts.

Additionally, Beacon Biosignals quantifies sleep microarchitecture to unlock novel biomarkers for neurodegenerative and psychiatric diseases. The company’s Datastore™ enables the extraction of custom cohorts to precisely match target patient populations and includes clinical-grade EEG data from thousands of individuals without CNS disease, accelerating the discovery of disease-specific neurobiomarkers. Beacon Biosignals’ analytic reports summarize subject- and cohort-level results, including clinical EEG interpretation by qualified neurologists, and offer cloud-based EEG viewer support for end-to-end clinician workflows. Their network of epileptologists provides central EEG reading services augmented by AI to improve efficiency and ensure standardization.